目的： 此回溯性研究分析吸入性colistin用於加護病房重症病人因多重抗藥性革蘭氏陰性菌導致呼吸器相關肺炎的治療結果與副作用。
方法： 由某區域教學醫院篩選自2010年3月1日至2011年3月1日期間住內外科加護病房中，大於18歲，使用呼吸器48小時後感染肺炎，氣管抽吸檢體或支氣管肺泡灌洗檢體培養為革蘭氏陰性菌包括綠膿桿菌和鮑氏不動桿菌，且使用吸入性colistin大於72小時的病人。
結果： 本研究共收入35個內外科加護病房病人，以吸入性colistin輔助治療後的臨床與微生物反應結果分別為62.9%和77.1%而死亡率為34.3%。此外本研究於治療期間未觀察到與吸入性colistin相關的副作用。
結論： 使用吸入性colistin可輔助治療多重抗藥性革蘭性陰性菌造成的呼吸器相關肺炎時，但相關研究仍不多，建議未來可做更嚴謹的隨機對照研究來證實此藥物的效果與副作用。
 

Objective: This retrospective study was focused on the efficacy and safety of nebulized colistin for critically ill patients with ventilator-associated pneumonia caused by multidrug-resistant gram negative bacteria in the intensive care unit.

Methods: A retrospective chart review was performed at a local teaching hospital from March 1st of 2010 to March 1st of 2011. We reviewed medical records of patients who were over 18 years old and had received aerosolized colistin for the treatment of ventilator-associated pneumonia with multidrug-resistant gram negative bacteria (Pseudomonas aeruginosa and Acinetobacter baumannii complex) in the medical and surgical intensive care unit.

Results: Thirty-five critically ill patients in the medical and surgical intensive care units were collected. The clinical and microbiologic response rates after administrating nebulized colistin were 62.9% and 77.1%, respectively. The mortality rate was 34.3%. No adverse effect associated with inhaled colistin was observed.

Conclusion: Nebulized colistin may be an adjuvant to treat ventilator-associated pneumonia with multidrug-resistance gram negative bacteria but its role in therapy warrants further investigation in comparative studies.